Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 133
Filter
2.
Am J Physiol Regul Integr Comp Physiol ; 309(11): R1432-8, 2015 Dec 01.
Article in English | MEDLINE | ID: mdl-26354847

ABSTRACT

We examined blood flow in the submandibular gland (SMGBF) and sublingual gland (SLGBF) during electrical stimulation of the central cut end of the lingual nerve (LN) in the urethane-anesthetized rats using a laser speckle imaging flow meter. LN stimulation elicited intensity- and frequency-dependent SMGBF and SLGBF increases, and the magnitude of the SMGBF increase was higher than that of the SLGBF increase. The increase in both glands was significantly inhibited by intravenous administration of the autonomic cholinergic ganglion blocker hexamethonium. The antimuscarinic agent atropine markedly inhibited the SMGBF increase and partly inhibited the SLGBF increase. The atropine-resistant SLGBF increase was significantly inhibited by infusion of vasoactive intestinal peptide (VIP) receptor antagonist, although administration of VIP receptor antagonist alone had no effect. The recovery time to the basal blood flow level was shorter after LN stimulation than after administration of VIP. However, the recovery time after LN stimulation was significantly delayed by administration of atropine in a dose-dependent manner to the same level as after administration of VIP. Our results indicate that 1) LN stimulation elicits both a parasympathetic SMGBF increase mainly evoked by cholinergic fibers and a parasympathetic SLGBF increase evoked by cholinergic and noncholinergic fibers, and 2) VIP-ergic mechanisms are involved in the noncholinergic SLGBF increase and are activated when muscarinic mechanisms are deactivated.


Subject(s)
Arteries/innervation , Lingual Nerve/physiology , Parasympathetic Nervous System/physiology , Sublingual Gland/blood supply , Submandibular Gland/blood supply , Vasodilation , Acetylcholine/metabolism , Animals , Blood Flow Velocity , Dose-Response Relationship, Drug , Electric Stimulation , Ganglionic Blockers/administration & dosage , Hormone Antagonists/administration & dosage , Laser-Doppler Flowmetry , Lingual Nerve/drug effects , Lingual Nerve/metabolism , Male , Muscarinic Antagonists/administration & dosage , Parasympathetic Nervous System/drug effects , Parasympathetic Nervous System/metabolism , Rats, Wistar , Regional Blood Flow , Time Factors , Vagotomy , Vasoactive Intestinal Peptide/metabolism , Vasodilation/drug effects
3.
Hypertension ; 63(2): 303-8, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24324040

ABSTRACT

The autonomic nervous system plays a central role in both acute and chronic blood pressure regulation in humans. The activity of the sympathetic branch of the autonomic nervous system is positively associated with peripheral resistance, an important determinant of mean arterial pressure in men. In contrast, there is no association between sympathetic nerve activity and peripheral resistance in women before menopause, yet a positive association after menopause. We hypothesized that autonomic support of blood pressure is higher after menopause in women. We examined the effect of ganglionic blockade on arterial blood pressure and how this relates to baseline muscle sympathetic nerve activity in 12 young (25±1 years) and 12 older postmenopausal (61±2 years) women. The women were studied before and during autonomic blockade using trimethaphan camsylate. At baseline, muscle sympathetic nerve activity burst frequency and burst incidence were higher in the older women (33±3 versus 15±1 bursts/min; 57±5 versus 25±2 bursts/100 heartbeats, respectively; P<0.05). Muscle sympathetic nerve activity bursts were abolished by trimethaphan within minutes. Older women had a greater decrease in mean arterial pressure (-29±2 versus -9±2 mm Hg; P<0.01) and total peripheral resistance (-10±1 versus -5±1 mm Hg/L per minute; P<0.01) during trimethaphan. Baseline muscle sympathetic nerve activity was associated with the decrease in mean arterial pressure during trimethaphan (r=-0.74; P<0.05). In summary, our results suggest that autonomic support of blood pressure is greater in older women compared with young women and that elevated sympathetic nerve activity in older women contributes importantly to the increased incidence of hypertension after menopause.


Subject(s)
Aging/physiology , Blood Pressure/physiology , Hypertension/physiopathology , Sympathetic Nervous System/physiology , Vascular Resistance/physiology , Adult , Blood Pressure/drug effects , Brachial Artery/innervation , Brachial Artery/physiology , Female , Ganglionic Blockers/administration & dosage , Humans , Menopause/physiology , Middle Aged , Muscle, Skeletal/innervation , Muscle, Skeletal/physiology , Peroneal Nerve/physiology , Sympathetic Nervous System/drug effects , Trimethaphan/administration & dosage , Vascular Resistance/drug effects , Vasodilator Agents/administration & dosage , Young Adult
4.
Crit Care Med ; 41(5): 1276-85, 2013 May.
Article in English | MEDLINE | ID: mdl-23388515

ABSTRACT

OBJECTIVES: Among enterovirus 71 infections, brainstem encephalitis progressing abruptly to cardiac dysfunction and pulmonary edema causes rapid death within several hours. However, no currently known early indicators and treatments can monitor or prevent the unexpectedly fulminant course. We investigate the possible mechanisms and treatment of fatal enterovirus 71 infections to prevent the abrupt progression to cardiac dysfunction and pulmonary edema by using an animal model. DESIGN: Treatment study. SETTING: Research laboratory. SUBJECTS: Sprague-Dawley rats. INTERVENTIONS: We microinjected 6-hydroxydopamine or vitamin C into nucleus tractus solitarii of the rat and evaluated the cardiopulmonary changes after treatment with ganglionic blocker. MEASUREMENTS AND MAIN RESULTS: The time course of changes in the heart and lungs of rats with brainstem lesions were investigated. Rats were administered 6-hydroxydopamine to induce brainstem lesions, causing acute hypertension in 10 minutes and acute elevations of catecholamines accompanied by acute cardiac dysfunction and increased strong expressions of connexin 43 gap junction protein in heart and lung specimens by immunohistochemical staining within 3 hours. Severe pulmonary hemorrhagic edema was produced within 6 hours, and the rats expired rapidly within 7 hours. After hexamethonium treatment, it was found that the acute hypertension induced by 6-hydroxydopamine lesions was immediately reversed and the acute high rise of catecholamine serum level was significantly attenuated within 3 hours, accompanied by preserved cardiac output and decreased expressions of connexin 43 in the heart and lungs. No pulmonary edema occurred and the rats survived for more than 14 hours. CONCLUSIONS: Early hexamethonium treatment attenuates acute excessive release of catecholamines to prevent cardiac dysfunction and pulmonary edema for increasing survival rate.


Subject(s)
Encephalitis, Viral/drug therapy , Enterovirus Infections/drug therapy , Hexamethonium/administration & dosage , Hypertension/prevention & control , Pulmonary Edema/prevention & control , Animals , Biopsy, Needle , Brain Stem/drug effects , Brain Stem/pathology , Catecholamines/metabolism , Diagnosis, Differential , Disease Models, Animal , Encephalitis, Viral/complications , Encephalitis, Viral/mortality , Encephalitis, Viral/pathology , Enterovirus A, Human/pathogenicity , Enterovirus Infections/complications , Enterovirus Infections/mortality , Enterovirus Infections/pathology , Ganglionic Blockers/administration & dosage , Hypertension/etiology , Hypertension/pathology , Immunohistochemistry , Male , Pulmonary Edema/etiology , Pulmonary Edema/pathology , Random Allocation , Rats , Rats, Sprague-Dawley , Survival Rate
5.
Neuropharmacology ; 63(5): 863-72, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22727822

ABSTRACT

Nicotine is the main active component of tobacco, and has both acute and chronic pharmacological effects that can contribute to its abuse potential in humans. The aim of the present study was to evaluate a possible role of GABA(B) receptors in acute and chronic responses to nicotine administration, by comparing GABA(B1) knockout mice and their wild-type littermates. In wild-type mice, acute nicotine administration (0.5, 1, 3 and 6 mg/kg, sc) dose-dependently decreased locomotor activity, and induced antinociceptive responses in the tail-immersion and hot-plate tests. In GABA(B1) knockout mice, the hypolocomotive effect was observed only with the highest dose of nicotine, and the antinociceptive responses in both tests were significantly reduced in GABA(B1) knockout mice compared to their wild-type littermate. Additionally, nicotine elicited anxiolytic- (0.05 mg/kg) and anxiogenic-like (0.8 mg/kg) responses in the elevated plus-maze test in wild-type mice, while selectively the anxiolytic-like effect was abolished in GABA(B1) knockout mice. We further investigated nicotine withdrawal in mice chronically treated with nicotine (25 mg/kg/day, sc). Mecamylamine (1 mg/kg, sc) precipitated several somatic signs of nicotine withdrawal in wild-type mice. However, signs of nicotine withdrawal were missing in GABA(B1) knockout mice. Finally, there was a decreased immunoreactivity of Fos-positive nuclei in the bed nucleus of the stria terminalis, basolateral amygdaloid nucleus and hippocampal dentate gyrus in abstinent wild-type but not in GABA(B1) knockout mice. These results reveal an interaction between the GABA(B) system and the neurochemical systems through which nicotine exerts its acute and long-term effects.


Subject(s)
Ganglionic Stimulants/toxicity , Motor Activity/drug effects , Nicotine/toxicity , Nicotinic Agonists/toxicity , Receptors, GABA-B/metabolism , Tobacco Use Disorder/physiopathology , Amygdala/drug effects , Amygdala/metabolism , Amygdala/pathology , Analgesics, Non-Narcotic/administration & dosage , Analgesics, Non-Narcotic/toxicity , Animals , Anti-Anxiety Agents/administration & dosage , Anti-Anxiety Agents/toxicity , Anxiety/chemically induced , Behavior, Animal , Dentate Gyrus/drug effects , Dentate Gyrus/metabolism , Dentate Gyrus/pathology , Dose-Response Relationship, Drug , Ganglionic Blockers/administration & dosage , Ganglionic Blockers/pharmacology , Ganglionic Stimulants/administration & dosage , Ganglionic Stimulants/antagonists & inhibitors , Injections, Subcutaneous , Mice , Mice, Inbred BALB C , Mice, Knockout , Nicotine/administration & dosage , Nicotine/antagonists & inhibitors , Nicotinic Agonists/administration & dosage , Nicotinic Agonists/chemistry , Nicotinic Antagonists/administration & dosage , Nicotinic Antagonists/pharmacology , Pain Threshold/drug effects , Receptors, GABA-B/genetics , Septal Nuclei/drug effects , Septal Nuclei/metabolism , Septal Nuclei/pathology , Tobacco Use Disorder/metabolism
6.
Exp Physiol ; 97(12): 1292-304, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22581746

ABSTRACT

Evidence suggests that the muscle mechanoreflex, a circulatory reflex that raises blood pressure and heart rate (HR) upon activation of mechanically sensitive afferent fibres in skeletal muscle, is overactive in hypertension. However, the mechanisms underlying this abnormal reflex function have yet to be identified. Sensory input from the mechanoreflex is processed within the nucleus tractus solitarii (NTS) in the medulla oblongata. Within the NTS, the enzymatic activity of nitric oxide synthase produces nitric oxide (NO). This centrally derived NO has been shown to modulate muscle reflex activity and serves as a viable candidate for mediating the mechanoreflex dysfunction that develops in hypertension. We hypothesized that mechanoreflex dysfunction in hypertension is mediated by abnormal alterations in NO production in the NTS. Mechanically sensitive afferent fibres were stimulated by passively stretching hindlimb muscle before and after blocking the endogenous production of NO within the NTS via microdialysis of the NO synthase inhibitor L-NAME (1 and 5 mM) in normotensive Wistar-Kyoto rats and spontaneously hypertensive rats (SHRs). Changes in HR and mean arterial pressure in response to stretch were significantly larger in SHRs compared with Wistar-Kyoto rats prior to L-NAME dialysis. Attenuating NO production via L-NAME in normotensive rats recapitulated the exaggerated cardiovascular response to stretch observed in SHRs. Dialysing L-NAME in SHRs further accentuated the increases in HR and mean arterial pressure elicited by stretch. These findings support the contention that reductions in NO production within the NTS contribute to the generation of abnormal cardiovascular control by the skeletal muscle mechanoreflex in hypertension.


Subject(s)
Blood Pressure , Hypertension/metabolism , Mechanotransduction, Cellular , Muscle Spindles/physiopathology , Muscle, Skeletal/innervation , Nitric Oxide/metabolism , Reflex, Stretch , Solitary Nucleus/metabolism , Animals , Blood Pressure/drug effects , Disease Models, Animal , Enzyme Inhibitors/administration & dosage , Ganglionic Blockers/administration & dosage , Heart Rate , Hexamethonium/administration & dosage , Hypertension/physiopathology , Male , Microdialysis , NG-Nitroarginine Methyl Ester/administration & dosage , Nitric Oxide Synthase/antagonists & inhibitors , Nitric Oxide Synthase/metabolism , Rats , Rats, Inbred SHR , Rats, Inbred WKY , Solitary Nucleus/drug effects , Solitary Nucleus/physiopathology , Time Factors
7.
J Child Adolesc Psychopharmacol ; 22(3): 198-205, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22537359

ABSTRACT

OBJECTIVE: To explore possible benefits of a nicotinic acetylcholine receptor (nAChR) agent for autistic symptoms based on postmortem observation of nAChR abnormalities (deficient α4ß2 nAChRs, excess α7 nAChRs) in brains of patients with autism. METHOD: Mecamylamine, because of its safety record in children with other disorders, was chosen for this first exploration. Twenty children with autism spectrum disorder age 4-12 years were randomly assigned for 14 weeks to placebo (n=8) or mecamylamine (n=12) in ascending fixed doses: 0.5 mg/day for 6 weeks, 2.5 mg for 2 weeks, then 5 mg/day for 6 weeks. Improvement was rated by a blinded independent evaluator. Because of small sample, data analysis was descriptive. RESULTS: Eighteen participants (10 mecamylamine, 8 placebo) completed the study. All doses were well tolerated; the only side effect of note was constipation (50% compared with 25% of placebo group). Three children had clinically nonsignificant electrocardiographic QT prolongation. Both groups showed modest to moderate improvement, but differences between groups were negligible. On the primary outcome measure, the Ohio Autism Clinical Impressions Scale, 90% of the active treatment group showed improvement at some point (but only 40% sustained it), compared with 62% on placebo. Of the four in active treatment that sustained improvement, three had a maximum dose of 0.13-0.15 mg/kg/day, while those who regressed had doses ≥0.18 mg/kg/day. Graphed means suggested better outcome with lower mg/kg and longer medication duration. Four parents spontaneously reported reduced hyperactivity and irritability and better verbalization and continued mecamylamine at their own expense. CONCLUSION: Mecamylamine appeared to be safe, but not very effective in autism. The suggestion of better results at lower doses and longer exposure warrants consideration for future trials. The next step would be exploration of a more specific α4ß2 nAChR agonist, such as varenicline.


Subject(s)
Child Development Disorders, Pervasive/drug therapy , Ganglionic Blockers/therapeutic use , Mecamylamine/therapeutic use , Child , Child, Preschool , Constipation/chemically induced , Dose-Response Relationship, Drug , Double-Blind Method , Female , Ganglionic Blockers/administration & dosage , Ganglionic Blockers/adverse effects , Humans , Male , Mecamylamine/administration & dosage , Mecamylamine/adverse effects , Pilot Projects , Treatment Outcome
8.
Clin Gastroenterol Hepatol ; 10(2): 186-91, 191.e1, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21946121

ABSTRACT

BACKGROUND & AIMS: The efficacy of endoscopic ultrasound-guided celiac plexus blockade (EUS-CPB) for painful chronic pancreatitis (CP) is uncertain. Triamcinolone is often mixed with bupivacaine to lengthen the analgesic effect. We investigated whether addition of triamcinolone increases and lengthens pain relief compared with EUS-CPB with only bupivacaine. METHODS: We performed a single-center, blinded, randomized, controlled trial of 40 adult patients referred for EUS-CPB for treatment of painful CP. Patients were assigned randomly to groups that received EUS-CPB with triamcinolone and bupivacaine or EUS-CPB with only bupivacaine (control). Questionnaires were collected when the study began (baseline) and 1 month later. The primary end point was a decrease in the pain disability index of 10 or more points at 1 month after the procedure. Secondary end points included change in visual analogue scale, narcotic requirements, and quality of life at 1 month. RESULTS: There were no significant differences in primary outcomes between groups (14.3% for patients who received triamcinolone vs 15.8% for controls; P = .64). The trial was stopped for futility. There was no significant difference between groups in immediate response rates (85.7% for patients who received triamcinolone vs 68.4% for control; P = .10), or other secondary end points, including change in pain visual analogue scale (0.4 vs 1.0; P = .83), treatment with morphine equivalents at 1 month (-7.8 vs 0.0; P = .35), change in quality of life at 1 month (SF-12 mental component: 1.3 vs -2.1; P = .44; and physical component: -0.2 vs 1.7; P = .54), or adverse events. The duration of response was shorter in the triamcinolone group (mean, 5.3 vs 0.6 mo; P = .01). CONCLUSIONS: Triamcinolone does not increase pain relief or lengthen the effects of EUS-CPB.


Subject(s)
Anesthetics, Local/administration & dosage , Celiac Plexus/drug effects , Endoscopy/methods , Ganglionic Blockers/administration & dosage , Pain/drug therapy , Pancreatitis, Chronic/complications , Triamcinolone/administration & dosage , Adult , Bupivacaine/administration & dosage , Drug Therapy, Combination/methods , Female , Humans , Male , Severity of Illness Index , Surveys and Questionnaires , Time Factors , Treatment Outcome
10.
J Hypertens ; 28(9): 1862-74, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20543714

ABSTRACT

BACKGROUND AND AIM: Structural changes in the large resistance vessels in hypertension amplify resistance responses in vitro, but their role in vivo has been controversial. To resolve this matter, we re-examined earlier data in Page hypertension. METHODS: Total peripheral resistance (TPR) and total peripheral conductance (TPC) responsiveness were compared in hypertensive and normotensive rabbits, 5 weeks after bilateral renal cellophane wrapping or sham operation. The rabbits were studied with effectors intact; during ganglionic blockade; during neurohumoral blockade (NHB). For each condition extended scaled dose (ScD)-TPC and TPR curves were derived from individual dose-response curves to two constrictors and two dilators. RESULTS: The ScD-response curves had two major nonlinearities: at high constrictor doses, due to functional (reversible) rarefaction (reduction in microcirculatory density); at high dilator doses, due to impaired autoregulation. The amplifier is best assessed during NHB over the intervening ScD range, by determining the TPR and TPC ratios from hypertensive and normotensive rabbits. Over this range the hypertensive: normotensive (H: N) ratio averaged 1.88 +/- 0.03 TPR units and was the same for constrictor and dilator responses, suggesting a structural basis; the resting H: N TPR ratio was also closely similar. At higher ScDs functional rarefaction developed initially at a greater rate in normotensive than in hypertensive rabbits. We conjecture that this was because some permanent rarefaction had already developed in hypertensive rabbits since the onset of hypertension. CONCLUSION: The systemic structural TPR amplifier is haemodynamically important in vivo and contributes to hypertension.


Subject(s)
Hypertension, Renal/physiopathology , Vascular Resistance/physiology , Acetylcholine/administration & dosage , Adenosine/administration & dosage , Angiotensin II/administration & dosage , Animals , Blood Vessels/drug effects , Blood Vessels/pathology , Blood Vessels/physiopathology , Cellophane , Disease Models, Animal , Dose-Response Relationship, Drug , Female , Ganglionic Blockers/administration & dosage , Hypertension, Renal/etiology , Hypertension, Renal/pathology , Male , Methoxamine/administration & dosage , Rabbits , Vascular Resistance/drug effects , Vasoconstrictor Agents/administration & dosage , Vasodilator Agents/administration & dosage
11.
Pain Med ; 11(3): 390-4, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20447308

ABSTRACT

BACKGROUND AND OBJECTIVES: Ganglion impar block is an uncommon procedure that has been performed traditional with fluoroscopy. One approach is the trans-sacrococcygeal approach. Sometimes this can be difficult because the sacrococcygeal joint (SCJ) cannot be readily seen on anteroposterior (AP) and lateral fluoroscopy. This technical report describes the feasibility of ultrasound in assisting ganglion impar blocks. METHODS: We performed ganglion impar block using ultrasound as the primary imaging tool, with fluoroscopic confirmation in 15 patients. We used a linear array transducer (5-12 MHz) to obtain sonographic transverse and longitudinal views at the sacral cornua; we identified the first cleft below the sacral hiatus as the SCJ. Then we inserted a 23-gauge (7 cm in length) needle into the SCJ under sonographic guidance. Then we confirmed proper needle depth by lateral fluoroscopy and injection of contrast agent. RESULTS: In all 15 procedures, we accurately located and passed the needle into the patients' SCJs under real time sonographic guidance. CONCLUSIONS: In cases where the cleft cannot be readily seen on AP and lateral fluoroscopy, we have found ultrasound to be of assistance. Ultrasound does not replace fluoroscopy, because lateral fluoroscopy is still required to establish safe depth, and correct site of injection. However, ultrasound can be helpful when fluoroscopy alone is insufficient.


Subject(s)
Ganglia, Sympathetic/diagnostic imaging , Nerve Block/methods , Contrast Media/administration & dosage , Feasibility Studies , Fluoroscopy , Ganglionic Blockers/administration & dosage , Humans , Needles , Prone Position , Sacrococcygeal Region/diagnostic imaging , Ultrasonography
12.
Am J Physiol Heart Circ Physiol ; 297(5): H1638-46, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19734362

ABSTRACT

The present study tested the hypotheses that 1) nitric oxide (NO) is involved in attenuated responses to ANG II in female mice, and 2) there is differential expression of neuronal NO synthase (nNOS) in the subfornical organ (SFO) and paraventricular nucleus (PVN) in response to systemic infusions of ANG II in males vs. females. Aortic blood pressure (BP) was measured in conscious mice with telemetry implants. N(G)-nitro-l-arginine methyl ester (l-NAME; 100 microg x kg(.-1)day(-1)), an inhibitor of NOS, was administrated into the lateral cerebral ventricle for 14 days before and during ANG II pump implantation. Central infusion of l-NAME augmented the pressor effects of systemic ANG II in females (Delta21.5 + or - 2.2 vs. Delta9.2 + or - 1.5 mmHg) but not in males (Delta29.4 + or - 2.5 vs. Delta30.1 + or - 2.5 mmHg). Central administration of N(5)-(1-imino-3-butenyl)-l-ornithine (l-VNIO), a selective nNOS inhibitor, also significantly potentiated the increase in BP induced by ANG II in females (Delta17.5 + or - 3.2 vs. Delta9.2 + or - 1.5 mmHg). In gonadectomized mice, central l-NAME infusion did not affect the pressor response to ANG II in either males or females. Ganglionic blockade after ANG II infusion resulted in a greater reduction in BP in central l-NAME- or l-VNIO-treated females compared with control females. Western blot analysis of nNOS protein expression indicated that levels were approximately 12-fold higher in both the SFO and PVN of intact females compared with those in intact males. Seven days of ANG II treatment resulted in a further increase in nNOS protein expression only in intact females (PVN, to approximately 51-fold). Immunohistochemical studies revealed colocalization of nNOS and estrogen receptors in the SFO and PVN. These results suggest that NO attenuates the increase in BP induced by ANG II through reduced sympathetic outflow in females and that increased nNOS protein expression associated with the presence of female sex hormones plays a protective role against ANG II-induced hypertension in female mice.


Subject(s)
Blood Pressure , Estrogens/metabolism , Hypertension/prevention & control , Nitric Oxide Synthase Type I/metabolism , Nitric Oxide/metabolism , Paraventricular Hypothalamic Nucleus/enzymology , Receptors, Estrogen/metabolism , Subfornical Organ/enzymology , Angiotensin II/administration & dosage , Animals , Blood Pressure/drug effects , Blotting, Western , Disease Models, Animal , Enzyme Inhibitors/administration & dosage , Female , Ganglionic Blockers/administration & dosage , Hexamethonium/administration & dosage , Hypertension/chemically induced , Hypertension/enzymology , Hypertension/physiopathology , Immunohistochemistry , Infusion Pumps, Implantable , Infusions, Subcutaneous , Male , Mice , Mice, Inbred C57BL , NG-Nitroarginine Methyl Ester/administration & dosage , Nitric Oxide Synthase Type I/antagonists & inhibitors , Orchiectomy , Ornithine/administration & dosage , Ornithine/analogs & derivatives , Ovariectomy , Paraventricular Hypothalamic Nucleus/drug effects , Sex Factors , Subfornical Organ/drug effects , Sympathetic Nervous System/physiopathology , Telemetry , Time Factors , Up-Regulation
13.
Am J Physiol Regul Integr Comp Physiol ; 297(4): R1111-7, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19675280

ABSTRACT

Neurogenic pulmonary edema (NPE) is an acute life-threatening complication following an injury of the spinal cord or brain, which is associated with sympathetic hyperactivity. The role of nitric oxide (NO) in NPE development in rats subjected to balloon compression of the spinal cord has not yet been examined. We, therefore, pretreated Wistar rats with the NO synthase inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME) either acutely (just before the injury) or chronically (for 4 wk prior to the injury). Acute (but not chronic) L-NAME administration enhanced NPE severity in rats anesthetized with 1.5% isoflurane, leading to the death of 83% of the animals within 10 min after injury. Pretreatment with either the ganglionic blocker pentolinium (to reduce blood pressure rise) or the muscarinic receptor blocker atropine (to lessen heart rate decrease) prevented or attenuated NPE development in these rats. We did not observe any therapeutic effects of atropine administered 2 min after spinal cord compression. Our data indicate that NPE development is dependent upon a marked decrease of heart rate under the conditions of high blood pressure elicited by the activation of the sympathetic nervous system. These hemodynamic alterations are especially pronounced in rats subjected to acute NO synthase inhibition. In conclusion, nitric oxide has a partial protective effect on NPE development because it attenuates sympathetic vasoconstriction and consequent baroreflex-induced bradycardia following spinal cord injury.


Subject(s)
Baroreflex , Nitric Oxide/metabolism , Pulmonary Edema/prevention & control , Spinal Cord Injuries/metabolism , Sympathetic Nervous System/physiopathology , Anesthetics, Inhalation/toxicity , Animals , Atropine/administration & dosage , Baroreflex/drug effects , Blood Pressure , Bradycardia/etiology , Bradycardia/physiopathology , Bradycardia/prevention & control , Disease Models, Animal , Drug Administration Schedule , Enzyme Inhibitors/administration & dosage , Ganglionic Blockers/administration & dosage , Heart Rate , Hypertension/etiology , Hypertension/physiopathology , Hypertension/prevention & control , Isoflurane/toxicity , Male , Muscarinic Antagonists/administration & dosage , NG-Nitroarginine Methyl Ester/administration & dosage , Nitric Oxide Synthase/antagonists & inhibitors , Nitric Oxide Synthase/metabolism , Pentolinium Tartrate/administration & dosage , Pulmonary Edema/etiology , Pulmonary Edema/metabolism , Pulmonary Edema/physiopathology , Rats , Rats, Wistar , Spinal Cord Injuries/complications , Spinal Cord Injuries/drug therapy , Spinal Cord Injuries/physiopathology , Sympathetic Nervous System/drug effects , Time Factors , Vasoconstriction
14.
Anesth Analg ; 108(5): 1701-4, 2009 May.
Article in English | MEDLINE | ID: mdl-19372357

ABSTRACT

BACKGROUND: In the present study, we describe and show the efficacy of a lateral approach to stellate ganglion block (SGB) in rats. METHODS: Twenty-one rats were randomized into three groups: the posterior technique group (n = 7), the lateral technique group (n = 7), and the control group (n = 7). Thiopental was administered intraperitonally as 5 mg per 100 g of each rat's weight for sedation during the procedure. In the posterior technique group, SGB was performed by a posterior percutaneous approach as described previously. In the lateral technique and control groups, the cervical vertebrae was fixed between the left first and third fingers of the physician's left hand while palpating the C7 process with the second finger. The study drug was 0.2 mL 0.25% plain bupivacaine for the two percutaneous treatment groups, and 0.2 mL saline in the controls. RESULTS: Two animals in the posterior technique group died immediately after local anesthetic injection (P < 0.01). There were no deaths in the new technique group or in the controls. Ptosis appeared at 300 +/- 120 s in the posterior group, whereas it was seen almost immediately after withdrawing the needle in the lateral technique group (6 +/- 4 s) (P < 0.001). Ptosis did not occur in the control group. There was no statistically significant difference in heart rate among groups (P > 0.069). CONCLUSION: The lateral approach to SGB does not require the induction of general anesthesia. The approach is associated with early development of ptosis and may be associated with a lower mortality rate compared to the conventional posterior approach.


Subject(s)
Anesthetics, Local/administration & dosage , Autonomic Nerve Block/methods , Bupivacaine/administration & dosage , Ganglionic Blockers/administration & dosage , Stellate Ganglion/drug effects , Animals , Blepharoptosis/chemically induced , Cervical Vertebrae , Heart Rate/drug effects , Hypnotics and Sedatives/administration & dosage , Injections, Intraperitoneal , Male , Rats , Rats, Sprague-Dawley , Thiopental/administration & dosage , Time Factors
15.
Exp Brain Res ; 194(4): 563-70, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19225770

ABSTRACT

This study was undertaken to elucidate neural control of the arterial blood pressure (ABP) in head-down postural change which causes both stimulation to the vestibular system and head-ward fluid shift. Experiments were carried out with urethane-anesthetized rabbits. The animal was mounted on a tilting table, tilted to 45 degrees head-down in 5 s, and kept at the position for 5 min. The head-down rotation (HDR) induced a transient decrease in ABP (10 +/- 3 mmHg; mean +/- SE), and then the pressure gradually recovered toward the pre-HDR level during the 5 min at the head-down position. Pretreatment with hexamethonium bromide, a ganglionic transmission blocker, suppressed the HDR-induced drop of ABP, suggesting that the ABP drop was induced by an inhibition of autonomic neural outflows. Renal sympathetic nerve activity (RSNA) decreased considerably after 1.6 +/- 0.2 s from the onset of HDR, which was followed by the ABP drop. Aortic depressor nerve activity (ADNA), an afferent for baroreceptor reflex, increased significantly during the rotation, but the peak of ADNA increase was 3.2 +/- 0.5 s after the initiation of the HDR. Therefore, the suppression of RSNA seems to be induced mainly by a quicker mechanism than baroreceptor reflex. In order to test the possibility, we examined changes in ABP and RSNA during HDR using vestibular-lesioned rabbits. In these rabbits, RSNA and ABP did not change significantly during HDR. These results suggest that vestibular organs play a role in the transient drop in ABP induced by HDR through the suppression of sympathetic nerve outflows.


Subject(s)
Blood Pressure/physiology , Head-Down Tilt/physiology , Vestibule, Labyrinth/physiology , Analysis of Variance , Anesthesia , Anesthetics, Intravenous/administration & dosage , Animals , Baroreflex/physiology , Blood Pressure/drug effects , Ganglionic Blockers/administration & dosage , Hexamethonium/administration & dosage , Rabbits , Sympathetic Nervous System/drug effects , Sympathetic Nervous System/physiology , Urethane/administration & dosage
16.
Anaesthesist ; 57(7): 689-92, 2008 Jul.
Article in German | MEDLINE | ID: mdl-18463832

ABSTRACT

A variation of the cranial carotid artery is demonstrated in an anatomical specimen revealing possible complications of ganglionic local opioid analgesia at the superior cervical ganglion. Located in the area of the puncture site, a loop of the aberrant carotid artery adheres closely to the pharyngeal wall in the medial position, shortening the distance between the arterial lumen and the oral cavity to 5 mm. With an incidence of 25%, an aberrant carotid artery could possibly facilitate an accidental intravascular injection during ganglionic local opioid application at the superior cervical ganglion.


Subject(s)
Analgesics, Opioid/adverse effects , Anesthesia, Conduction/adverse effects , Carotid Arteries/abnormalities , Ganglionic Blockers/adverse effects , Superior Cervical Ganglion/abnormalities , Analgesics, Opioid/administration & dosage , Carotid Arteries/anatomy & histology , Ganglionic Blockers/administration & dosage , Humans , Injections, Intravenous , Neck/surgery , Pharynx/anatomy & histology , Pharynx/surgery , Risk Factors , Superior Cervical Ganglion/anatomy & histology
17.
Clin Pharmacol Ther ; 83(5): 692-701, 2008 May.
Article in English | MEDLINE | ID: mdl-17687267

ABSTRACT

The purpose of this study was to compare ganglionic blockade with trimethaphan (TMP) and an alternative drug strategy using combined muscarinic antagonist (glycopyrrolate, GLY) and alpha-2 agonist (dexmedetomidine, DEX). Protocol 1: incremental phenylephrine was administered during control and combined GLY-DEX, or control and TMP on two control combined GLY and DEX or TMP infusion on two randomized days. Protocol 2: muscle sympathetic nerve activity (MSNA) and the baroreflex MSNA relationship was determined before and after GLY-DEX. Blood pressure was higher with GLY-DEX (99+/-3 mm Hg) and lower with TMP (78+/-3 mm Hg) relative to control (GLY-DEX: 90+/-2 mm Hg; TMP: 91+/-2 mm Hg; P<0.05). Incremental phenylephrine increased pressure during GLY-DEX (P<0.01 vs control) and TMP (P<0.01 vs control) to a similar degree. Both GLY-DEX and TMP infusion inhibited norepinephrine release (P<0.01 vs control). GLY-DEX inhibited baseline MSNA (P<0.05) and baroreflex changes in MSNA (P<0.01). We conclude that the GLY-DEX alternative drug strategy can be used as a reasonable alternative to pharmacologic ganglionic blockade to examine autonomic cardiovascular control.


Subject(s)
Cardiovascular System/drug effects , Dexmedetomidine/administration & dosage , Ganglionic Blockers/administration & dosage , Glycopyrrolate/administration & dosage , Trimethaphan/administration & dosage , Adrenergic alpha-Agonists/administration & dosage , Adult , Autonomic Nerve Block/methods , Baroreflex/drug effects , Baroreflex/physiology , Cardiac Output/drug effects , Cardiovascular System/innervation , Catecholamines/metabolism , Female , Heart Rate/drug effects , Humans , Male , Muscarinic Antagonists/administration & dosage , Phenylephrine/administration & dosage , Sympathetic Nervous System/drug effects
18.
J Neurosci Res ; 86(3): 712-9, 2008 Feb 15.
Article in English | MEDLINE | ID: mdl-17893924

ABSTRACT

The periaqueductal gray area (PAG) is a mesencephalic area involved in cardiovascular modulation. Noradrenaline (NA), a neurotransmitter involved in central blood pressure control, is present in the rat PAG. We report here on the cardiovascular effects caused by NA microinjection into the ventrolateral PAG (vlPAG) of unanesthetized rats and the peripheral mechanism involved in their mediation. NA microinjection in the vlPAG of unanesthetized rats evoked dose-related pressor and bradycardiac responses. No significant cardiovascular responses were observed in urethane-anesthetized rats. The pressor response was potentiated by pretreatment with the ganglion blocker pentolinium (5 or 10 mg/kg, intravenously). Pretreatment with the vasopressin antagonist dTyr(CH2)5 (Me)AVP (50 microg/kg, intravenously) blocked the pressor response evoked by the NA microinjection into the vlPAG. Additionally, circulating vasopressin content was found to be significantly increased after NA microinjection in the vlPAG. The results suggest that activation of noradrenergic synapses within the vlPAG modulates vasopressin release in unanesthetized rats.


Subject(s)
Cardiovascular System/drug effects , Norepinephrine/administration & dosage , Periaqueductal Gray , Vasoconstrictor Agents/administration & dosage , Anesthetics, Intravenous , Animals , Arginine Vasopressin/administration & dosage , Arginine Vasopressin/analogs & derivatives , Arginine Vasopressin/pharmacology , Blood Pressure/drug effects , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Synergism , Ganglionic Blockers/administration & dosage , Ganglionic Blockers/pharmacology , Heart Rate/drug effects , Hormone Antagonists/administration & dosage , Hormone Antagonists/pharmacology , Injections, Intravenous , Male , Microinjections , Norepinephrine/antagonists & inhibitors , Norepinephrine/pharmacology , Pentolinium Tartrate/administration & dosage , Pentolinium Tartrate/pharmacology , Rats , Rats, Wistar , Urethane , Vasoconstrictor Agents/antagonists & inhibitors , Vasoconstrictor Agents/pharmacology , Vasopressins/antagonists & inhibitors , Vasopressins/blood
19.
Anesthesiology ; 107(2): 264-72, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17667571

ABSTRACT

BACKGROUND: Neuronal nicotinic acetylcholine receptors are both potently inhibited by anesthetics and densely expressed in the thalamus. Brain imaging shows that thalamic activity suppression accompanies anesthetic-induced unconsciousness. Therefore, anesthetic-induced unconsciousness may involve direct antagonism of thalamic nicotinic receptors. The authors test this by separately attempting to block or enhance anesthetic-induced loss of righting in rats using intrathalamic microinjections of nicotine or its antagonist. METHODS: Rats were implanted with a cannula aimed at the thalamus or control locations. A week later, loss of righting was induced using sevoflurane (1.4 +/- 0.2%). A dose-parameter study (n = 35) first identified an optimal intrathalamic nicotine dose associated with arousal. Subsequently, this dose was used to pinpoint the thalamic site mediating the arousal response (n = 107). Finally, sevoflurane righting dose and response specificity were assessed after blocking nicotinic channels with intrathalamic mecamylamine pretreatment (n = 8) before nicotine challenge. RESULTS: Nicotine (150 microg/0.5 microl over 1 min) was the optimal arousal dose, because lower doses (75 microg) were ineffective and higher doses (300 microg) often caused seizures. Nicotine temporarily restored righting and mobility in animals when microinjections involved the central medial thalamus (P < 0.0001, chi-square). Righting occurred despite continued sevoflurane administration. Intrathalamic mecamylamine pretreatment did not lower the sevoflurane dose associated with loss of righting, but prevented the nicotine arousal response. CONCLUSIONS: The reversal of unconsciousness found here with intrathalamic microinfusion of nicotine suggests that suppression of the midline thalamic cholinergic arousal system is part of the mechanism by which anesthetics produce unconsciousness.


Subject(s)
Anesthetics, Inhalation/adverse effects , Ganglionic Stimulants/pharmacology , Methyl Ethers/adverse effects , Nicotine/pharmacology , Reflex, Abnormal/drug effects , Thalamus/drug effects , Anesthetics, Inhalation/administration & dosage , Animals , Arousal/drug effects , Behavior, Animal/drug effects , Consciousness/drug effects , Dose-Response Relationship, Drug , Ganglionic Blockers/administration & dosage , Ganglionic Stimulants/administration & dosage , Mecamylamine/administration & dosage , Methyl Ethers/administration & dosage , Microinjections , Nicotine/administration & dosage , Rats , Rats, Sprague-Dawley , Sevoflurane
20.
Rev. Soc. Esp. Dolor ; 14(2): 113-116, mar. 2007. ilus
Article in Es | IBECS | ID: ibc-055702

ABSTRACT

Objetivo Valorar la eficacia y seguridad del abordaje transdiscal coccígeo para el bloqueo con anestésicos locales y corticoides del ganglio de Walter en la coccigodinia. Pacientes y Método Estudiamos prospectivamente 6 pacientes, 4 mujeres (66´6%) y 2 hombres ( 33,4%) , con coccigodinia de más de 6 meses de duración, de origen benigno y puntuación media 6 en la escala analógica visual (EVA). Se llevó a cabo el abordaje del ganglio de Walter para su bloqueo (con anestésicos locales y corticoides) por vía transdiscal coccígea en quirófano. Se evaluó la eficacia analgésica, el grado de satisfacción y las complicaciones. Resultados Cinco de los seis pacientes, fueron dados de alta sin dolor (EVA<1). El total de la muestra manifestó estar satisfecho con el tratamiento. Tras cuatro meses de seguimiento, no registramos complicaciones. Conclusiones El abordaje transdiscal del ganglio de Walter es sencillo, seguro (con menos riesgo de perforación del recto y de inyección peri-ósea de la solución, que la vía clásica utilizada para su bloqueo) y eficaz en el tratamiento de la coccigodinia


Objetive To test the efficacy and safety of the Walter ganglion blockade trough coccygeal disc, in patients who suffered from coccygodynia. Patients and Methods We evaluated six patients, 4 women (66,6%) and two men (33,4%), with chronic coccyx pain (>6 months), and more than 6 points in Visual Analogue Scale (VAS). We described the trans-coccygeal disc approach to Walter ganglion blockade technique. The improvement of pain score, degree of satisfaction and complications of the patients were evaluated. Results Five patients improved VAS score 6 to 1. All the patients were satisfied with the treatment. We had no complications. Conclusions The trans-discal approach of the Walter ganglion is easy, safe (with less risk of rectal perforation and bone traumatism than the classical ano-coccygeal ligament via), and effective for chronic coccygodynia


Subject(s)
Humans , Sacrococcygeal Region/physiopathology , Low Back Pain/therapy , Ganglionic Blockers/administration & dosage , Adrenal Cortex Hormones/administration & dosage , Anesthetics, Local/administration & dosage , Hypogastric Plexus
SELECTION OF CITATIONS
SEARCH DETAIL
...